Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 24 Jun 2013 |
| Zealand’s presentation at the Jefferies 2013 Global Healthcare Conference to be webcast | 31 May 2013 |
| Zealand and Helsinn announce Helsinn’s decision to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea | 28 May 2013 |
| Zealand to present at upcoming global healthcare investor conferences in the US | 21 May 2013 |
| Zealand Pharma A/S ─ Interim report for Q1 2013 (un-audited) | 15 May 2013 |
| Notice of Zealand’s Interim Report for Q1 2013 | 8 May 2013 |